When FDA Trust Is Broken: Lessons from the MedLink Scandal
A recent FDA announcement has sent shockwaves through the MedTech community: MedLink, a third-party test house, was found falsifying test data. The consequences? All pending FDA submissions that relied on MedLink’s data have been rejected, delaying or derailing device approvals and costing companies precious time and trust.
In this episode of MedDevice by Design, Ariana Wilson and Mark Drlik examine what happened, what it means for medical device innovators, and how the FDA’s ASCA (Accreditation Scheme for Conformity Assessment) program helps reduce regulatory risk.
What Happened with MedLink?
The FDA discovered that MedLink had falsified testing data, compromising the integrity of submissions relying on that information. As a result, those submissions are now invalid, and the affected companies must retest their devices and resubmit, costing them months of delay and significant financial loss.
Why ASCA Accreditation Matters
To prevent this kind of disruption, the FDA established the ASCA program in 2020. Labs that receive ASCA accreditation are thoroughly vetted, giving the FDA and submitting companies greater confidence in their test results. Submissions that include ASCA-accredited data benefit from reduced review times—sometimes shaving weeks or even months off approval timelines.
The Tradeoff: Fewer Labs, Higher Costs
As of late 2024, only 47 test houses hold ASCA accreditation, limiting access for some companies. Additionally, ASCA-accredited testing can be 10% to 30% more expensive than non-accredited alternatives. Still, that investment offers peace of mind and regulatory security—especially when the risk of working with an unreliable lab is so high.
Key Takeaway: Prioritize Risk Management
This episode is a reminder of the critical role third-party labs play in the regulatory process. Choosing an ASCA-accredited lab is not just about speed; it’s about reducing risk, protecting your investment, and ensuring trust in your data.
Enjoying MedDevice by Design? Sign up to get new episodes sent to your inbox.
Related Resources
Accelerated aging in medical devices is a testing method used to estimate how a product will perform over time by exposing it to elevated conditions, most often heat. In simple terms, it is a way to simulate months or years of aging in a much shorter timeframe.
In a recent article for MD+DI, StarFish Medical Software Manager Sean Daniel explores how remote medical devices reliability is becoming a defining challenge as devices move beyond traditional clinical environments into homes, workplaces, and public settings.
This medical vs wellness example shows how device classification can directly change functionality. Even when hardware is similar, what the device is allowed to do can be very different.
Modern medical devices are no longer confined to hospital settings. Wearable cardiac monitors, home respiratory systems, and remote patient monitoring devices now operate within broader digital health networks.